Literature DB >> 18839328

Serum fibroblast growth factor-23 levels in chronic haemodialysis patients.

Salwa Ibrahim1, Laila Rashed.   

Abstract

BACKGROUND: Fibroblast growth factor-23 (FGF23) is a circulating factor that regulates renal reabsorption of inorganic phosphate. Serum FGF23 level is increased in chronic kidney disease (CKD) patients as a compensatory mechanism to hyperphosphataemia. FGF23 directly signals in the parathyroid glands and can be used to predict future secondary hyperparathyroidism in dialysis patients. We examined the relationship between FGF23 and serum calcium, phosphate, 1,25(OH)(2)D(3), and PTH levels in haemodialysis patients.
METHODS: FGF23 and the above mentioned characteristics were measured in 50 chronic haemodialysis patients. We analysed the correlation between FGF23 and the other characteristics by using the Pearson correlation coefficient and multiple regression analysis.
RESULTS: FGF23 was significantly increased in haemodialysis patients compared with healthy controls (1525 +/- 373 vs. 37 +/- 9 pg/ml, P < 0.0001). There was a significant negative correlation between log FGF23 and 1,25(OH)(2)D(3) (R = -0.375, P = 0.009) and a significant positive correlation between log FGF23 and log PTH values (R = 0.287, P = 0.041). In multiple regression analysis log PTH and 1,25(OH)(2)D(3) values were independent predictors of log FGF23 (P = 0.037 and 0.009, respectively).
CONCLUSIONS: Our results revealed a marked increase in FGF23 levels in haemodialysis patients. PTH and vitamin D3 were independent predictors of FGF23 in the study group. Serum phosphate did not correlate with or predict FGF23 level despite the high prevalence of hyperphosphataemia in the study group.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18839328     DOI: 10.1007/s11255-008-9466-0

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  27 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 2.  FGFs, heparan sulfate and FGFRs: complex interactions essential for development.

Authors:  D M Ornitz
Journal:  Bioessays       Date:  2000-02       Impact factor: 4.345

Review 3.  The role of fibroblast growth factor 23 in renal disease.

Authors:  Kenneth B Jonsson
Journal:  Nephrol Dial Transplant       Date:  2005-03       Impact factor: 5.992

4.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

Authors:  Shiguang Liu; Wen Tang; Jianping Zhou; Jason R Stubbs; Qiang Luo; Min Pi; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

5.  Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

Authors:  Hitoshi Saito; Akira Maeda; Shu-Ichi Ohtomo; Michinori Hirata; Kenichiro Kusano; Shigeaki Kato; Etsuro Ogata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

6.  Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Authors:  Shohei Nakanishi; Junichiro James Kazama; Tomoko Nii-Kono; Kentaro Omori; Takeyoshi Yamashita; Seiji Fukumoto; Fumitake Gejyo; Takashi Shigematsu; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

7.  FGF-23 is elevated by chronic hyperphosphatemia.

Authors:  A Gupta; K Winer; M J Econs; S J Marx; M T Collins
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

8.  Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.

Authors:  Takashi Shigematsu; Junichiro James Kazama; Takeyoshi Yamashita; Seiji Fukumoto; Tatsuo Hosoya; Fumitake Gejyo; Masafumi Fukagawa
Journal:  Am J Kidney Dis       Date:  2004-08       Impact factor: 8.860

9.  Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients.

Authors:  P Urena Torres; G Friedlander; M C de Vernejoul; C Silve; D Prié
Journal:  Kidney Int       Date:  2007-10-17       Impact factor: 10.612

10.  Effects of parathyroidectomy on bone remodeling markers and vitamin D status in patients with chronic kidney disease-mineral and bone disorder.

Authors:  Barbara Santarosa Emo Peters; Rosa Maria Affonso Moyses; Vanda Jorgetti; Lígia Araújo Martini
Journal:  Int Urol Nephrol       Date:  2007-08-07       Impact factor: 2.370

View more
  5 in total

1.  Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.

Authors:  Justine Bacchetta; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-02-05       Impact factor: 3.714

2.  Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism.

Authors:  Tomasz Hryszko; Szymon Brzosko; Alicja Rydzewska-Rosolowska; Ewa Koc-Zorawska; Michal Mysliwiec
Journal:  Int Urol Nephrol       Date:  2011-08-27       Impact factor: 2.370

Review 3.  The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

Review 4.  The consequences of chronic kidney disease on bone metabolism and growth in children.

Authors:  Justine Bacchetta; Jérôme Harambat; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Nephrol Dial Transplant       Date:  2012-08       Impact factor: 5.992

5.  Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients.

Authors:  Kensaku Shibata; Shu-Ichi Fujita; Hideaki Morita; Yusuke Okamoto; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.